Orchid To Develop Merck’s Anti-Coagulant; To Buy Majority Stake In Diakron
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Chennai-based injectible cephalosporin manufacturer Orchid Chemicals will develop and manufacture an oral anti-coagulant drug that was initially discovered by U.S. drug maker MerckYou may also be interested in...
Merck's Chief Strategy Officer Mervyn Turner Talks To PharmAsia News About Partnerships And Transformational Research Models
Mervyn J. Turner, Merck's chief strategy officer and senior vice president for emerging markets is entrusted with the responsibility of forging research partnerships with companies across the globe. Turner evaluates pipelines and capabilities of companies that can benefit the core drug discovery functions at Merck's laboratories and as part of that function, he is building partnerships with companies in India such as Ranbaxy, Piramal Healthcare, Orchid and Advinus. On a visit to India recently, Turner sat down with PharmAsia News' India bureau to elaborate on his future ideas.
Merck's Chief Strategy Officer Mervyn Turner Talks To PharmAsia News About Partnerships And Transformational Research Models
Mervyn J. Turner, Merck's chief strategy officer and senior vice president for emerging markets is entrusted with the responsibility of forging research partnerships with companies across the globe. Turner evaluates pipelines and capabilities of companies that can benefit the core drug discovery functions at Merck's laboratories and as part of that function, he is building partnerships with companies in India such as Ranbaxy, Piramal Healthcare, Orchid and Advinus. On a visit to India recently, Turner sat down with PharmAsia News' India bureau to elaborate on his future ideas.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports